Delayed Diagnosis of Transthyretin Amyloid Cardiomyopathy in the Veterans Health Administration
JACC · 2026-02 · 87 (5) · 533-545
DOI: 10.1016/j.jacc.2025.10.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC, 2026-02. Verfasst von Gabriela Spencer-Bonilla und 13 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California, USA; Division of Cardiovascular Medicine, Department of Medici…. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Delayed Diagnosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Timely diagnosis and treatment are critical to reduce morbidity and mortality for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Limited existing data suggest underdiagnosis of ATTR-CM and inequity in predictors of diagnosis patterns. OBJECTIVE: This study sought to describe the time from heart failure (HF) diagnosis to ATTR-CM diagnosis and identify predictors for delayed diagnosis of ATTR-CM. METHODS: This retrospective cohort study used Veterans Health Administration (VHA) data. We identified patients with HF and ATTR-CM diagnosed between 2016 and 2022 using an algorithm based on diagnoses and medications. The primary outcome was the time to diagnosis of ATTR-CM and was defined as the number of days between each patient's first HF diagnosis and their first ATTR-CM diagnosis. We also evaluated the number of days between first HF hospitalization or first loop diuretic prescription and ATTR-CM diagnosis. We used multivariable logistic regression to assess demographic, clinical, and socioeconomic predictors of time to ATTR-CM diagnosis using >6 months as a meaningful delay. RESULTS: A total of 2,557 patients with HF and ATTR-CM were identified. The mean age at the time of ATTR-CM diagnosis was 81 years. Most veterans were male (2,544; 99.5%) and White (1,440; 56%). The median time to diagnosis to ATTR-CM was 490 days. For the 1,882 veterans with a loop diuretic prescription before ATTR-CM diagnosis, the median time between initial loop prescription and ATTR-CM diagnosis was 835 days (Q1-Q3: 250-1850). Across Department of Veterans Affairs sites, the median number of days to diagnosis ranged from 169 to 1,070 days. After adjustment, Black race (OR: 0.71; 95% CI: 0.57-0.88) and older age (OR: 0.66; 95% CI: 0.59-0.73) were associated with a shorter time to diagnosis, whereas a history of atrial fibrillation (OR: 1.21; 95% CI: 1.00-1.45), coronary artery disease (OR: 1.38; 95% CI: 1.15-1.64), or chronic kidney disease (OR: 1.79; 95% CI: 1.50-2.15) was associated with longer time to diagnosis. CONCLUSIONS: There are clinically important delays between incident HF and diagnosis of ATTR-CM. Carrying a diagnosis of atrial fibrillation, coronary artery disease, or chronic kidney disease was associated with a longer delay to diagnosis. These findings uncover an opportunity for clinicians to consider concomitant ATTR-CM in patients with alternate etiologies for their cardiomyopathy, as expediting evaluation for ATTR-CM following HF diagnosis is critical to reduce the morbidity of this progressive condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California, USA; Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA;…
- Palo Alto Veterans Affairs Healthcare System, Palo Alto, California, USA.
- Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, Califo…
- U.S. Medical Affairs, BioPharmaceutical Medical, AstraZeneca, Wilmington, Delaware, USA.
Zitieren
APA
Spencer-Bonilla, G., Fan, J., Cheng, P., Varshney, A., Din, N., Rodriguez, F., Papas, M. A., Davies, M., Venditto, J., Huang, J., Witteles, R. M., Heidenreich, P. A., Alexander, K. M., & Sandhu, A. T. (2026). Delayed Diagnosis of Transthyretin Amyloid Cardiomyopathy in the Veterans Health Administration. JACC, 87(5), 533-545. https://doi.org/10.1016/j.jacc.2025.10.021
Vancouver
Spencer-Bonilla G, Fan J, Cheng P, Varshney A, Din N, Rodriguez F, et al. Delayed Diagnosis of Transthyretin Amyloid Cardiomyopathy in the Veterans Health Administration. JACC. 2026;87(5):533-545. doi:10.1016/j.jacc.2025.10.021
BibTeX
@article{SpencerBonilla2026,
author = {Spencer-Bonilla, Gabriela and Fan, Jun and Cheng, Paul and Varshney, Anubodh and Din, Natasha and Rodriguez, Fatima and Papas, Mia A and Davies, Marie and Venditto, John and Huang, Joanna and Witteles, Ronald M and Heidenreich, Paul A and Alexander, Kevin M and Sandhu, Alexander T},
title = {Delayed Diagnosis of Transthyretin Amyloid Cardiomyopathy in the Veterans Health Administration},
journal = {JACC},
year = {2026},
volume = {87},
number = {5},
pages = {533--545},
doi = {10.1016/j.jacc.2025.10.021}
}
EUVIMED